| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Fusion Protein:AGO2-CHRAC1 |
Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: AGO2-CHRAC1 | FusionPDB ID: 2901 | FusionGDB2.0 ID: 25711 | Hgene | Tgene | Gene symbol | AGO2 | CHRAC1 | Gene ID | 27161 | 54108 |
| Gene name | argonaute RISC catalytic component 2 | chromatin accessibility complex subunit 1 | |
| Synonyms | CASC7|EIF2C2|LINC00980|PPD|Q10 | CHARC1|CHARC15|CHRAC-1|CHRAC-15|CHRAC15|YCL1 | |
| Cytomap | 8q24.3 | 8q24.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | protein argonaute-2PAZ Piwi domain proteinargonaute 2, RISC catalytic componentcancer susceptibility candidate 7cancer susceptibility candidate 7 (non-protein coding)eukaryotic translation initiation factor 2C, 2long intergenic non-protein coding RN | chromatin accessibility complex protein 1DNA polymerase epsilon subunit p15chromatin accessibility complex 1chromatin accessibility complex 15 kDa proteinhistone-fold protein CHRAC15 | |
| Modification date | 20200327 | 20200313 | |
| UniProtAcc | Q9UKV8 | Q9NRG0 | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000220592, ENST00000519980, ENST00000517293, | ENST00000519533, ENST00000220913, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 13 X 13 X 12=2028 | 3 X 2 X 3=18 |
| # samples | 28 | 4 | |
| ** MAII score | log2(28/2028*10)=-2.85655892005837 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(4/18*10)=1.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context (manual curation of fusion genes in FusionPDB) | PubMed: AGO2 [Title/Abstract] AND CHRAC1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | AGO2(141645584)-CHRAC1(141524468), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | AGO2-CHRAC1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. AGO2-CHRAC1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | AGO2 | GO:0010501 | RNA secondary structure unwinding | 19966796 |
| Hgene | AGO2 | GO:0031054 | pre-miRNA processing | 16424907|17671087|18178619|19966796 |
| Hgene | AGO2 | GO:0035087 | siRNA loading onto RISC involved in RNA interference | 19966796 |
| Hgene | AGO2 | GO:0035196 | production of miRNAs involved in gene silencing by miRNA | 19966796|23661684 |
| Hgene | AGO2 | GO:0035278 | miRNA mediated inhibition of translation | 17671087|19801630 |
| Hgene | AGO2 | GO:0035279 | mRNA cleavage involved in gene silencing by miRNA | 15260970|17524464 |
| Hgene | AGO2 | GO:0035280 | miRNA loading onto RISC involved in gene silencing by miRNA | 18178619|19966796 |
| Hgene | AGO2 | GO:0045766 | positive regulation of angiogenesis | 27208409 |
| Hgene | AGO2 | GO:0045947 | negative regulation of translational initiation | 17524464|19801630 |
| Hgene | AGO2 | GO:0090625 | mRNA cleavage involved in gene silencing by siRNA | 15260970 |
| Hgene | AGO2 | GO:1905618 | positive regulation of miRNA mediated inhibition of translation | 23409027 |
| Fusion gene breakpoints across AGO2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across CHRAC1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Gene Sample Information |
| Fusion gene information from FusionGDB2.0. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | PAAD | TCGA-IB-A6UF-01A | AGO2 | chr8 | 141645584 | - | CHRAC1 | chr8 | 141524468 | + |
| ChimerDB4 | PAAD | TCGA-IB-A6UF | AGO2 | chr8 | 141615896 | - | CHRAC1 | chr8 | 141524468 | + |
| ChimerDB4 | PAAD | TCGA-IB-A6UF | AGO2 | chr8 | 141645584 | - | CHRAC1 | chr8 | 141524468 | + |
Top |
Fusion ORF Analysis |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000220592 | AGO2 | chr8 | 141645584 | - | ENST00000220913 | CHRAC1 | chr8 | 141524468 | + | 2274 | 135 | 550 | 804 | 84 |
| ENST00000519980 | AGO2 | chr8 | 141645584 | - | ENST00000220913 | CHRAC1 | chr8 | 141524468 | + | 2201 | 62 | 477 | 731 | 84 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000220592 | ENST00000220913 | AGO2 | chr8 | 141645584 | - | CHRAC1 | chr8 | 141524468 | + | 0.326039 | 0.673961 |
| ENST00000519980 | ENST00000220913 | AGO2 | chr8 | 141645584 | - | CHRAC1 | chr8 | 141524468 | + | 0.4380999 | 0.56190014 |
Top |
Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >2901_2901_1_AGO2-CHRAC1_AGO2_chr8_141645584_ENST00000220592_CHRAC1_chr8_141524468_ENST00000220913_length(amino acids)=84AA_BP= -------------------------------------------------------------- >2901_2901_2_AGO2-CHRAC1_AGO2_chr8_141645584_ENST00000519980_CHRAC1_chr8_141524468_ENST00000220913_length(amino acids)=84AA_BP= -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:141645584/chr8:141524468) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| AGO2 | CHRAC1 |
| FUNCTION: Required for RNA-mediated gene silencing (RNAi) by the RNA-induced silencing complex (RISC). The 'minimal RISC' appears to include AGO2 bound to a short guide RNA such as a microRNA (miRNA) or short interfering RNA (siRNA). These guide RNAs direct RISC to complementary mRNAs that are targets for RISC-mediated gene silencing. The precise mechanism of gene silencing depends on the degree of complementarity between the miRNA or siRNA and its target. Binding of RISC to a perfectly complementary mRNA generally results in silencing due to endonucleolytic cleavage of the mRNA specifically by AGO2. Binding of RISC to a partially complementary mRNA results in silencing through inhibition of translation, and this is independent of endonuclease activity. May inhibit translation initiation by binding to the 7-methylguanosine cap, thereby preventing the recruitment of the translation initiation factor eIF4-E. May also inhibit translation initiation via interaction with EIF6, which itself binds to the 60S ribosomal subunit and prevents its association with the 40S ribosomal subunit. The inhibition of translational initiation leads to the accumulation of the affected mRNA in cytoplasmic processing bodies (P-bodies), where mRNA degradation may subsequently occur. In some cases RISC-mediated translational repression is also observed for miRNAs that perfectly match the 3' untranslated region (3'-UTR). Can also up-regulate the translation of specific mRNAs under certain growth conditions. Binds to the AU element of the 3'-UTR of the TNF (TNF-alpha) mRNA and up-regulates translation under conditions of serum starvation. Also required for transcriptional gene silencing (TGS), in which short RNAs known as antigene RNAs or agRNAs direct the transcriptional repression of complementary promoter regions. {ECO:0000250|UniProtKB:Q8CJG0, ECO:0000255|HAMAP-Rule:MF_03031, ECO:0000269|PubMed:15105377, ECO:0000269|PubMed:15260970, ECO:0000269|PubMed:15284456, ECO:0000269|PubMed:15337849, ECO:0000269|PubMed:15800637, ECO:0000269|PubMed:16081698, ECO:0000269|PubMed:16142218, ECO:0000269|PubMed:16271387, ECO:0000269|PubMed:16289642, ECO:0000269|PubMed:16357216, ECO:0000269|PubMed:16756390, ECO:0000269|PubMed:16936728, ECO:0000269|PubMed:17382880, ECO:0000269|PubMed:17507929, ECO:0000269|PubMed:17524464, ECO:0000269|PubMed:17531811, ECO:0000269|PubMed:17932509, ECO:0000269|PubMed:18048652, ECO:0000269|PubMed:18178619, ECO:0000269|PubMed:18690212, ECO:0000269|PubMed:18771919, ECO:0000269|PubMed:19167051, ECO:0000269|PubMed:23746446}. | FUNCTION: Forms a complex with DNA polymerase epsilon subunit POLE3 and binds naked DNA, which is then incorporated into chromatin, aided by the nucleosome remodeling activity of ISWI/SNF2H and ACF1. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | CHRAC1 | chr8:141645584 | chr8:141524468 | ENST00000220913 | 0 | 3 | 100_124 | 49.0 | 132.0 | Coiled coil | Ontology_term=ECO:0000255 |
| - Not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000220592 | - | 1 | 19 | 235_348 | 7.333333333333333 | 860.0 | Domain | PAZ |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000220592 | - | 1 | 19 | 517_818 | 7.333333333333333 | 860.0 | Domain | Piwi |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000519980 | - | 1 | 18 | 235_348 | 7.333333333333333 | 826.0 | Domain | PAZ |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000519980 | - | 1 | 18 | 517_818 | 7.333333333333333 | 826.0 | Domain | Piwi |
Top |
Fusion Protein Structures |
| PDB and CIF files of the predicted fusion proteins * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
| Fusion protein PDB link (fusion AA seq ID in FusionPDB) | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | AA seq | Len(AA seq) |
| PDB file >>>12_AGO2_141645584_CHRAC1_141524468_ranked_0.pdb | AGO2 | 141645584 | 141645584 | ENST00000220913 | CHRAC1 | chr8 | 141524468 | + | 84 |
Top |
pLDDT score distribution |
| pLDDT score distribution of the predicted wild-type structures of two partner proteins from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
AGO2_pLDDT.png  |
CHRAC1_pLDDT.png  |
| pLDDT score distribution of the predicted fusion protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
 |
Top |
Ramachandran Plot of Fusion Protein Structure |
| Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide. |
| Fusion AA seq ID in FusionPDB and their Ramachandran plots |
Top |
Fusion Protein-Protein Interaction |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160) |
| Gene | PPI interactors |
| Protein-protein interactors based on sequence similarity (STRING) |
| Gene | STRING network |
| AGO2 | |
| CHRAC1 |
| - Retained interactions in fusion protein (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost interactions due to fusion (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000220592 | - | 1 | 19 | 311_316 | 7.333333333333333 | 860.0 | guide RNA |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000220592 | - | 1 | 19 | 524_566 | 7.333333333333333 | 860.0 | guide RNA |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000220592 | - | 1 | 19 | 709_710 | 7.333333333333333 | 860.0 | guide RNA |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000220592 | - | 1 | 19 | 753_761 | 7.333333333333333 | 860.0 | guide RNA |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000220592 | - | 1 | 19 | 790_812 | 7.333333333333333 | 860.0 | guide RNA |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000519980 | - | 1 | 18 | 311_316 | 7.333333333333333 | 826.0 | guide RNA |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000519980 | - | 1 | 18 | 524_566 | 7.333333333333333 | 826.0 | guide RNA |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000519980 | - | 1 | 18 | 709_710 | 7.333333333333333 | 826.0 | guide RNA |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000519980 | - | 1 | 18 | 753_761 | 7.333333333333333 | 826.0 | guide RNA |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000519980 | - | 1 | 18 | 790_812 | 7.333333333333333 | 826.0 | guide RNA |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000220592 | - | 1 | 19 | 587_590 | 7.333333333333333 | 860.0 | GW182 family members |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000220592 | - | 1 | 19 | 650_660 | 7.333333333333333 | 860.0 | GW182 family members |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000519980 | - | 1 | 18 | 587_590 | 7.333333333333333 | 826.0 | GW182 family members |
| Hgene | AGO2 | chr8:141645584 | chr8:141524468 | ENST00000519980 | - | 1 | 18 | 650_660 | 7.333333333333333 | 826.0 | GW182 family members |
Top |
Related Drugs to AGO2-CHRAC1 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to AGO2-CHRAC1 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies